Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 8/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | ABAT | P80404 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7566427 | 0.81 | TAAR1 (0.57) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL27600642 | 0.79 | SLC6A2 (0.61) | TAAR1SLC6A2 | |
| SCHEMBL5113171 | 0.79 | ESR1 (0.58) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL26800409 | 0.79 | ALOX15 (0.63) | TAAR1SLC6A2SLC7A5ESR1BLM | |
| SCHEMBL5424462 | 0.78 | TAAR1 (0.54) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL10253191 | 0.78 | SLC6A2 (0.58) | TAAR1SLC6A2SLC7A5 | |
| SCHEMBL14038762 | 0.78 | SLC6A2 (0.58) | TAAR1SLC6A2SLC7A5 | |
| SCHEMBL3843513 | 0.78 | SLC6A2 (0.58) | TAAR1SLC6A2SLC7A5 | |
| SCHEMBL27482590 | 0.78 | SLC7A5 (0.54) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL15153017 | 0.78 | TAAR1 (0.53) | TAAR1SLC6A2SLC7A5ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160376618-A1 | PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE AND RELATED DERIVATIVES | NORAMCO, LLC | 2016-12-29 | — | — | US | disclosed |
| US-9402819-B2 | Anti-HIV compound and preparation method and use thereof | SICHUAN UNIVERSITY (CN) | 2016-08-02 | — | — | US | disclosed |
| US-20150313853-A1 | ANTI-HIV COMPOUND AND PREPARATION METHOD AND USE THEREOF | SICHUAN UNIVERSITY (CN) | 2015-11-05 | — | — | US | disclosed |
| US-8198218-B2 | Heterocyclic compounds, combinatorial libraries thereof and methods of selecting drug leads | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2012-06-12 | — | — | US | disclosed |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-27 | — | — | US | disclosed |
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-12-23 | — | — | US | disclosed |
| US-20100022499-A1 | HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | PPM1D, PPM1G, PPM1F | TAAR1 596/4885SLC6A2 1417/4885SLC7A5 3768/4885 |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | PPM1F, PPM1D, PPP1R1B | TAAR1 1789/4885SLC6A2 3582/4885SLC7A5 4451/4885 |
| US-20160376618-A1 | PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE AND RELATED DERIVATIVES | COMT, MGAM, GAA | TAAR1 297/4885SLC6A2 14/4885SLC7A5 667/4885 |
| US-20100022499-A1 | HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS | AADAC, ABCG2, RICTOR | TAAR1 4707/4885SLC6A2 4065/4885SLC7A5 615/4885 |
| US-20150313853-A1 | ANTI-HIV COMPOUND AND PREPARATION METHOD AND USE THEREOF | FURIN, CD4, SI | TAAR1 4851/4885SLC6A2 805/4885SLC7A5 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.